Raymond James & Associates Virios Therapeutics, Inc. Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Virios Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 30,000 shares of VIRI stock, worth $7,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,000
Previous 30,000
-0.0%
Holding current value
$7,200
Previous $17,000
17.65%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VIRI
# of Institutions
22Shares Held
681KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA209KShares$50,1310.0% of portfolio
-
Geode Capital Management, LLC Boston, MA174KShares$41,8720.0% of portfolio
-
State Street Corp Boston, MA52.8KShares$12,6780.0% of portfolio
-
Mc Collum Christoferson Group LLC Amherst, NY42KShares$10,0800.01% of portfolio
-
Northern Trust Corp Chicago, IL24KShares$5,7680.0% of portfolio
About Virios Therapeutics, Inc.
- Ticker VIRI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,330,400
- Market Cap $4.4M
- Description
- Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC...